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Abstract
AIM: To investigate whether dysplastic Barrett’s 
Oesophagus can be safely and effectively treated 
endoscopically in low volume centres after structured 
training. 
METHODS: After attending a structured training 
program in Amsterdam on the endoscopic treatment 
of dysplastic Barrett’s Oesophagus, treatment of 
these patients was initiated at St Marys Hospital. This 
is a retrospective case series conducted at a United 
Kingdom teaching Hospital, of patients referred for 
endoscopic treatment of Barrett’s oesophagus with high 
grade dysplasia or early cancer, who were diagnosed 
between January 2008 and February 2012. Data 
was collected on treatment provided (radiofrequency 
ablation and endoscopic resection), and success of 
treatment both at the end of treatment and at follow 
up. Rates of immediate and long term complications 
were assessed. 
RESULTS: Thirty-two patients were referred to St 
Marys with high grade dysplasia or intramucosal cancer 
within a segment of Barrett’s Oesophagus. Twenty-
seven met the study inclusion criteria, 16 of these had 
a visible nodule at initial endoscopy. Treatment was 
given over a median of 5 mo, and patients received 
a median of 3 treatment sessions over this time. 
At the end of treatment dysplasia was successfully 
eradicated in 96% and intestinal metaplasia in 88%, on 
per protocol analysis. Patients were followed up for a 
median of 18 mo. At which time complete eradication 
of dysplasia was maintained in 86%. Complications 
were rare: 2 patients suffered from post-procedural 
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bleeding, 4 cases were complicated by oesophageal 
stenosis. Recurrence of cancer was seen in 1 case. 
CONCLUSION: With structured training good outcomes 
can be achieved in low volume centres treating 
dysplastic Barrett’s Oesophagus. 
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Core tip: With structured training endoscopic treatment 
of dysplastic Barrett’s Oesophagus with endoscopic 
resection and radiofrequency ablation can be provided 
in lower volume centres with good safety and efficacy 
outcomes. 
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INTRODUCTION
Barrett’s Oesophagus is a significant risk factor for oe­
sophageal cancer[1], with studies suggesting it develops 
through a dysplasia­carcinoma sequence[2]. As it does the 
risk of  progression to cancer increases from 0.1% per year 
for a non­dysplastic segment of  Barrett’s Oesophagus[3], to 
5.6% per year if  high grade dysplasia (HGD) is present[4]. 
United Kingdom guidelines recommend that Barrett’s 
Oesophagus should be regularly surveyed, with prompt 
intervention if  there is progression to HGD or cancer[5]. 
Until recently esophagectomy has been considered the 
treatment of  choice, but this is associated with significant 
morbidity and mortality even in high volume centres[6]. 
Over recent years significant progress has been made in 
the endoscopic treatment of  Barrett’s Oesophagus with 
dysplastic changes. This has resulted in the most recent 
United Kingdom guidelines recommending endoscopic 
treatment of  HGD in preference to oesophagectomy, 
given the lower treatment related morbidity[5]. 
Endoscopic treatment of  dysplastic Barrett’s oe­
sophagus has two important stages. First, removal of  
any visible dysplastic lesions. This is usually achieved 
by endoscopic mucosal resection (EMR) of  the lesion; 
this provides definitive staging information and ensures 
that lesions extending into the submucosa are not 
missed. Once this is done, it is recommended that any 
remaining segment of  Barrett’s Oesophagus is treated, 
this minimises the risk development of  cancer in the 
future in the remaining Barrett’s segment[7]. Two distinct 
approaches can be taken to do this, stepwise radical 
endoscopic resection (SRER) or ablation of  the affected 
mucosa. Over the last five years radiofrequency ablation 
(RFA) has become the most widely used ablative 
technique. A recent systematic review demonstrated that 
while SRER and RFA have similar efficacy in treating 
dysplastic Barrett’s Oesophagus, RFA is associated with a 
significantly lower rate of  complications[8]. Furthermore 
while SRER appears to be a relatively complex technique 
to learn[9], learning to perform RFA does not appear to 
be associated with such a significant learning curve[10]. 
Ablation is therefore generally accepted as the preferred 
treatment modality in Europe. 
To date most of  the studies looking at the endoscopic 
treatment of  Barrett’s Oesophagus have come from 
high volume research centres, with only one small 
retrospective study coming from a community hospital in 
the United States[11]. This study reported 100% success in 
eradication of  dysplasia at follow up in 10 patients with 
HGD, suggesting that dysplastic Barrett’s Oesophagus 
can be managed successfully outside of  large volume 
research centres. But larger studies performed outside 
high volume research centres are still needed. 
Given the rapidly rising incidence of  oesophageal cancer 
and Barrett’s Oesophagus in the United Kingdom[12,13], 
several smaller centres have established treatment programs 
for dysplastic Barrett’s Oesophagus. Recognising this 
fact the Academic Medical Centre in Amsterdam (AMC) 
created a multidisciplinary European Training Program for 
the treatment of  neoplasia within Barrett’s Oesophagus[14]. 
The aim of  this course was to improve the quality of  
detection and treatment of  dysplastic Barrett’s Oesophagus 
in these lower volume centres. 
This study aims to assess whether with the structured 
training, endoscopists with little experience in ablative 
techniques can be taught to manage dysplastic Barrett’s 
Oesophagus safely and effectively in lower volume centres. 
MATERIALS AND METHODS
Study design and patient population
In 2008 a centre for the treatment of  dysplastic Barrett’s 
oesophagus was established at St Mary’s, a United 
Kingdom teaching hospital and regional centre for upper 
gastro­intestinal surgery. Patients were included in this 
retrospective consecutive case series, if  they were diagnosed 
with Barrett’s Oesophagus with HGD or intramucosal 
cancer (IMC) between January 2008 and February 2012 and 
were referred to St Marys for endoscopic treatment. 
All patients had their pre­treatment histological 
diagnosis confirmed by a specialist pathologist (RG), and 
were discussed at the local specialist multi­disciplinary 
team (MDT) meeting, to determine the most appropriate 
treatment course. Any further staging investigations 
including CT and EUS recommended by the MDT to 
rule out invasive cancer, were performed at this stage. 
Patients were identified for inclusion in the study by 
searching the hospital’s electronic endoscopy database 
(Ascribe), records were cross checked against pathology 
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records and MDT meeting reports to ensure no cases 
were missed. Patients were excluded from this study if  
there was evidence of  sub­mucosal invasion on resection 
of  any visible nodules, or if  they were considered unfit 
for repeated therapeutic endoscopies. 
Teaching program at the AMC
Prior to the commencement of  the study period, a 
multi­disciplinary team from St Marys, consisting of  an 
endoscopist (JH), a pathologist (RG) and an endoscopy 
nurse attended the European training program for 
Barrett’s Oesophagus with neoplasia at the AMC. The 
course consisted of  three two day workshops, these 
combined theoretical lectures, live demonstrations by 
experts and finally hands on supervised training sessions. 
The hands on sessions were staged, starting treatment 
on explanted pig tissue, before progressing to live pigs 
and then human cases. A variety of  different endoscopic 
techniques were taught including EMR­cap, multiband 
mucosectomy and RFA. 
Endoscopic procedures
All endoscopic procedures were performed by one of  
two experienced endoscopists (JH, PV) on an outpatient 
basis under conscious sedation. All procedures were 
performed using an Olympus H260Z series endoscope, 
with narrow band imaging and zoom features used at the 
operators discretion. 
Visible areas of  dysplasia were resected first, using 
the DuetteTM Multiband Mucosectomy (Cook Medical, 
Winston­Salem, NC). Patients with evidence of  sub­
mucosal invasion on the resected specimen were referred 
back to the MDT, and excluded from the study at this 
stage. Remaining patients had a repeat endoscopy two 
months later, where a further resection was performed if  
required. Otherwise patients were considered for ablation 
of  any residual Barrett’s Oesophagus using RFA. Patients 
with dysplasia detected within a segment of  flat Barrett’s 
Oesophagus on initial endoscopy started treatment with 
RFA immediately. 
RFA was performed using the HALO system (BARRX 
Medical, Sunnyvale, CA). Circumferential RFA (HALO360) 
was usually applied first, using standard energy settings (12 
J/cm2, 40 W/cm2). This was repeated after repositioning 
the balloon, until the entire Barrett’s Oesophagus se­
gment was ablated. The catheter was then removed, so 
debris could be scraped off  the balloon and coagulum 
could be removed from the ablation zone. The process 
was then repeated, before ablating the segment a 
second time. If  there was only a short segment of  non­
circumferential Barrett’s Oesophagus present initially 
or on follow up procedures, focal ablation was applied 
using the HALO90 device. RFA was then delivered 
twice in quick succession to each area (12­15 J/cm2, 40 
W/cm2), then the probe and the mucosa were cleaned, 
the area was then ablated again twice. In the interest 
of  costs, argon plasma coagulation (APC) was used at 
the endoscopist’s discretion to treat small islands (< 5 
mm) of  residual Barrett’s Oesophagus. Patients received 
treatment at 2­3 monthly intervals until all visible Barrett’s 
Oesophagus was eradicated. 
At this stage treatment was considered complete 
and targeted biopsies were taken of  any endoscopic 
abnormalities in the oesophagus, and quadrantic biopsies 
were taken from just distal (< 5 mm) to the neo­
squamocolumnar junction (NSCJ). 
Histological analysis
All histological specimens were analysed by a specialist 
gastrointestinal pathologist (RG), and if  there was evi­
dence of  dysplasia the diagnosis was confirmed by a 
second pathologist. Biopsies were assessed using the 
revised Vienna classification[15]. 
Data collection
Data was collected retrospectively from endoscopy reports 
and pathology records, up to August 2013. Information 
was collected on patient demographics, length of  the 
Barrett’s Oesophagus segment treated, the number and 
type of  procedures each patient had had, duration of  
follow up and complications related to the procedure. 
Histology records provided information on pre and post 
treatment histology. 
Endpoints
The primary outcome assessed was success of  complete 
eradication of  dysplasia (CE­D) and intestinal metaplasia 
(CE-IM) after completion of  treatment. This was defined as 
absence of  any endoscopically visible Barrett’s Oesophagus 
(confirmed on available oesophageal biopsies), combined 
with the absence of  dysplasia on biopsies taken from just 
distal to the NSCJ. 
Secondary endpoints: (1) Rate of  CE­D/CE­IM at 
most recent follow­up endoscopy, more than 6 mo 
after completion of  treatment. Follow­up duration was 
defined as the time between completion of  treatment 
and the most recent follow up endoscopy; (2) Rates of  
short term complications, related to initial endoscopic 
procedure, e.g., bleeding or perforation; and (3) Rates of  
long term complications associated with the endoscopic 
treatment, e.g., oesophageal stenosis.
Results are presented on both a per protocol (PP) 
and an intention to treat (ITT) basis, for the primary 
outcome and complication rates. But follow up results are 
presented on intention to follow up basis, after excluding 
patients who did not complete endoscopic treatment (due 
to patient choice or failure of  endoscopic treatment) and 
patients who had not completed 6 mo follow up. 
Statistical analysis
The study did not use any biostatistics mathods.
RESULTS
Between January 2008 and February 2012, 32 patients 
were referred for endoscopic treatment of  Barrett’s 
Oesophagus with HGD or IMC.
Twenty­one of  these patients had a nodule visible 
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achieved in 85% (23/27) CE­D, while 78% (21/27) 
achieved CE­IM. But 3 patients did not complete 
treatment as planned, so for the 24 patients who 
completed treatment as planned CE­D was achieved in 
96% (23/24), with only 1 patient having evidence of  
residual low grade dysplasia (LGD). A further 2 patients 
who completed their planned treatment had evidence 
of  visible non­dysplastic Barrett’s Oesophagus after 
completing treatment, so CE­IM was achieved in 88% 
(21/24) of  the cohort on PP analysis.
One patient who did not complete planned tr­
eatment was lost to follow up, after failing to attend 
several appointments. He represented 2 years later 
with a T2 oesophageal cancer, this was treated with an 
oesophagectomy but he subsequently died. The other two 
patients were lost to follow up, despite multiple attempts 
to re­engage them. 
Secondary outcomes
Follow up results: 22 patients were considered for 
analysis in the follow up cohort. The 5 patients who 
were dropped from this cohort included the 3 patients 
who had failed to complete treatment, 1 who died from 
pancreatic cancer before starting follow up and 1 patient 
was referred for surgery after endoscopic treatment failed 
and resulted in a severe stricture refractory to endoscopic 
dilatation. The median follow up duration was 18 mo 
(range 7­34 mo). 
During follow up 3 patients had recurrence of  
dysplasia. One patient had recurrent IMC, this has been 
retreated endoscopically and the patient is awaiting follow 
up. One patient who had LGD at the end of  treatment 
endoscopically at referral. Of  these, 3 patients were found 
to have lesions extending deep into the submucosa, 
and an additional 2 patients were considered unfit 
for repeated endoscopic therapy due to severe co­
morbidities. As a result these 5 patients were excluded 
from analysis. 
This left 27 patients who met the inclusion criteria, 
and were considered for this study (Figure 1). Patient 
demographics are summarised in Table 1. 
Treatment received
Patients received treatment over a median of  5 mo. 
During this time the median number of  treatment 
sessions required was 3 (range 1­9). Where RFA was 
used, patients required a median of  1 focal and 1 
circumferential ablation.
Sixteen patients (59%), including all those with a 
known diagnosis of  IMC, had a nodule visible at initial 
endoscopy which was resected. Four of  these patients 
required a further endoscopic resection, during the 
treatment period. Following successful endoscopic 
resection, 14 patients received additional treatment with 
RFA to treat the remaining Barrett’s Oesophagus. 
While 11 patients were found to have evidence of  
dysplasia within a flat segment Barrett’s Oesophagus, they 
were treated with RFA alone as the primary therapy. 
Following EMR and RFA, additional treatment with 
APC was needed in 14 patients, to treat small areas of  
residual Barrett’s Oesophagus. 
Primary outcomes
On an ITT basis CE­D at the end of  treatment was 
69 January 16, 2015|Volume 7|Issue 1|WJGE|www.wjgnet.com
Patients referred to St Marys for 
endoscopic treatment of HGD/IMC of 
Barrett’s Oesophagus (n  = 32)
Patients treated endosopically (n  = 
27)
   2 EMR (1 required APC also)
   11 RFA (6 required APC also)
   14 EMR and RFA (7 required APC 
also)
Exclusions from intention to treat analysis:
   Evidence of submucosal invasion on EMR (n  = 3)
   Unfit for repeated endoscopies due to co-morbidities (n = 2)
Outcomes at end of treatment:
   23 CE-D
   21 CE-IM
   Treatment failures: 1 LGD, 2 residual IM (n  = 3)
   Did not complete treatment (n  = 3)
Exclusions from intention to follow-up analysis:
   Death before follow up (n  = 1)
   Did not complete treatment (n  = 3)
   Patient referred for surgery due to stricture (n  = 1)
Outcomes at end of follow-up treatment:
   19 CE-D
   14 CE-IM
   Treatment failures: 3 recurrent dysplasia, 5 recurrent 
IM (n  = 8)
Planned follow up (n  = 22)
Figure 1  Selection of analysis cohort and outcomes. HGD: High grade dysplasia; LGD: Low grade dysplasia; IMC: Intramucosal cancer; APC: Argon plasma 
coagulation; EMR: Endoscopic mucosal resection; CE-D: Complete eradication of dysplasia; CE-IM: Intestinal metaplasia.
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progressed to HGD during follow up. This patient is 
now undergoing regular surveillance instead of  further 
treatment, on account of  their co­morbidities and wishes. 
The final patient who developed LGD during follow 
up is undergoing more intense surveillance, but has 
not received further treatment. So overall 19/22 (86%) 
patients achieved CE­D at the most recent follow up.
A further 5 patients had recurrence of  visible non­
dysplastic Barrett’s Oesophagus during follow up, so CE­
IM was maintained in 14/22 (64%). 
Complication rates 
Overall 6 patients suffered from complications related 
to the procedure (22%). Two patients suffered acute 
bleeding post EMR, both were successfully treated 
endoscopically.
A further four (14.8%) patients developed oesophageal 
stenosis during follow up, all had had a prior EMR. 
This was treated successfully with endoscopic dilatation 
in three patients (two patients required a single 
dilatation, but one patient required three dilatations). 
The final patient, treated midway through the study, 
had five attempts at dilatation but the stricture was 
refractory to treatment, this patient was referred for an 
oesophagectomy which confirmed there was no evidence 
of  residual disease.
There were no fatalities or oesophageal perforations 
related to treatment. 
DISCUSSION
Given the high morbidity and mortality associated with 
oesophagectomy, endoscopic treatment for Barrett’s 
Oesophagus with HGD or IMC is now considered the 
treatment of  choice in most patients[5,16]. To date these 
treatments have been provided predominantly by high 
volume research centres. However, with the increasing 
prevalence of  oesophageal cancer and Barrett’s Oesophagus 
in Europe[12], an increasing number of  lower volume 
treatment centres are being established. As a result the 
AMC in Amsterdam developed a specialised training 
program aimed at optimising the recognition and 
treatment of  dysplastic Barrett’s Oesophagus in these 
centres. It is therefore important to establish whether 
similar outcomes, in terms of  both treatment efficacy 
and complication rates, can be achieved in lower volume 
centres after attending such a program. 
This retrospective case series started with the first 
case of  dysplastic Barrett’s Oesophagus treated at our 
institution after attending the course, and demonstrates 
that EMR and RFA for dysplastic Barrett’s Oesophagus 
can be safely performed in lower volume institutions 
outside of  a research setting. 
Analysis of  outcomes focused on the rates of  
eradication of  dysplasia and intestinal metaplasia at the 
end of  treatment and at follow up. For this analysis 
we considered presence of  dysplasia on biopsies taken 
below the neo­squamocolumnar junction as evidence 
of  treatment failure, because studies have suggested the 
risk of  recurrence of  dysplasia is highest in this area and 
may predict development of  neoplasia[17,18]. But presence 
of  intestinal metaplasia alone below the NSCJ was not 
considered significant, as the relevance of  this finding is 
debatable. Morales et al[19] demonstrated the presence of  
intestinal metaplasia in routine biopsies taken from the 
cardia in 25% of  a healthy population, suggesting the 
finding is not clinically relevant[19].
Overall treatment was very successful in patients 
who completed treatment as planned, with 100% 
success in eradication of  HGD and IMC, 96% success 
in eradication of  any dysplasia and 88% success in 
eradicating visible Barrett’s Oesophagus. These results are 
comparable to previous studies, with prospective studies 
from large volume tertiary referral centres reporting 
between 81%­100% CE­D and 74%­100% CE­IM at the 
end of  treatment[20­24]. 
One of  the major drawbacks of  studies to date has 
been the short follow up periods reported, between 14 
and 22 mo[20­24]. This study provides a median follow up 
of  18 mo. Overall durability of  eradication of  dysplasia 
was good, with 86% of  patients maintaining complete 
eradication of  dysplasia at the end of  treatment. Previous 
studies had reported 79%­100% CE­D at follow 
up[20­22,25,26].
Currently St Marys is a relatively low volume centre, 
with only 32 new patients considered for treatment 
during the 4 year study period (equating to less than 1 
new patient per month). So our patient volumes are likely 
to be similar to those reported by centres involved in the 
United Kingdom HALO registry. This registry collected 
data from 216 patients recruited from 14 United Kingdom 
centres, and reported the following outcomes at the end 
of  treatment: 83% CE­HGD, 76% CE­D and 50% CE­
IM[27]. It is uncertain what initial training endoscopists 
had at each centre involved in this study. But our 
comparatively favourable results suggest that access to a 
specialised training program may have a beneficial impact 
on treatment outcomes, and allow lower volume centres 
to provide access to high quality endoscopic treatment 
for dysplastic Barrett’s Oesophagus. 
Throughout this series there were no reported deaths 
or perforations, but two patients required endoscopic 
treatment for bleeding post EMR. A further four patients 
(14.8%) suffered late complications, due to oesophageal 
stenosis. Our overall rates of  oesophageal stenosis was 
slightly higher than rates reported in previous studies (0%
­14%)[20­23,26,28,29]. This can be explained by two factors, 
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Table 1  Patient demographics
Male: female 25:2
Median age (yr) (range) 66 (53-89)
Median length Barrett’s (cm) (range) 5 (1-10)
Worst diagnosis on biopsy or ER specimen 9 IMC/18 HGD
Chadwick G et al . Management of dysplastic Barrett’s Oesophagus
HGD: High grade dysplasia; LGD: Low grade dysplasia; IMC: Intra-
mucosal cancer.
firstly the relatively high proportion of  patients (59%) 
who required EMR prior to use of  RFA (it should be 
noted that all strictures in this study occurred in patients 
who had had a previous EMR) and secondly this series 
started with the first case treated by our endoscopists. 
Van Vilsteren et al[9] previously demonstrated that there 
is a significant learning curve associated with learning to 
perform oesophageal EMR, and noted that complication 
rates were highest for the first few therapeutic en­
doscopies performed[9]. 
In conclusion, this study demonstrates that following 
structured training good outcomes can be achieved in the 
endoscopic treatment of  dysplastic Barrett’s Oesophagus 
in lower volume centres. While our rate of  oesophageal 
stenosis was slightly higher than previously reported, it 
must be noted that these results represent the start of  
our learning curve. We therefore expect this rate to fall as 
the endoscopist’s experience increases. 
COMMENTS
Background
Barrett’s Oesophagus is a pre-malignant condition which progresses through 
a dysplasia-carcinoma sequence. As it does the risk of progression to cancer 
increases rapidly. It is therefore important to treat patients with evidence of high 
grade dysplasia as they are at higher risk of developing oesophageal cancer. 
Until recently oesophagectomy has been the mainstay of treatment this is 
associated with significant risk, and therefore used predominantly in younger 
fitter patients. But recently newer endoscopic techniques have been developed 
with proven safety and efficacy in treating dysplastic Barrett’s Oesophagus. 
Research frontiers
With the increasing incidence of Barrett’s Oesophagus in the United Kingdom it 
is important to assess whether these endoscopic techniques can be used safely 
and effectively outside of research centres, where the majority of the current 
literature is derived. 
Innovations and breakthroughs
Several large studies have already demonstrated the safety and efficacy of 
endoscopic resection and radiofrequency ablation in dysplastic Barrett’s Oesophagus 
(as summarised in a review by Chadwick et al). But these studies have come 
from high volume research centres. This is the first study to demonstrate that 
with structured training clinicians can achieve good outcomes in the endoscopic 
treatment of dysplastic Barrett’s Oesophagus in low volume centres. 
Applications
The results of this study suggest that with structured training, endoscopic 
treatment of dysplastic Barrett’s can be used safely and effectively in lower 
volume hospitals. 
Terminology
Barrett’s Oesophagus: This is the replacement of the normal stratified 
epithelium lining of the lower oesophagus with columnar cells. This is important 
because it puts the person at increased risk of development of oesophageal 
cancer; Dysplasia: Refers to the development of abnormal epithelium, which 
in the case of Barrett’s Oesophagus is at risk of progression to cancer; 
Intramucosal oesophageal cancer: Cancer affecting the very superficial layer of 
the oesophagus. This stage of cancer is at low risk of spreading to the regional 
lymph nodes and distant organs; Endoscopic Mucosal Resection: A procedure 
to remove cancerous or other abnormal tissues (lesions) using an endoscope 
which is passed down the oesophagus. Radiofrequency ablation is the use of 
high frequency current to destroy areas of abnormal tissue. 
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